112257-19-9

Basic information

• Product Name: tert-butyl methyl(2-(methylamino)ethyl)carbamate
• Synonyms: Carbamic acid, methyl[2-(methylamino)ethyl]-, 1,1-dimethylethyl ester;tert-butyl methyl[2-(methylamino)ethyl]carbamate(SALTDATA: FREE);N-Methyl-N'-Methyl-N'-t-butoxycarbonylethylenediaMine;tert-butyl N-Methyl-N-[2-(MethylaMino)ethyl]carbaMate;[2-(Methylamino)ethyl](methyl)carbamic acid tert-butyl ester;[2-[(tert-Butoxycarbonyl)(methyl)amino]ethyl]methylamine;tert-Butyl methyl(2-(methylamino);tert-butyl methyl(2-(methylamino)ethyl)carbamate
• CAS NO: 112257-19-9
• Molecular Formula: C₉H₂₀N₂O₂
• Molecular Weight: 188.2673
• Mol File: 112257-19-9.mol

Chemical Properties

• Boiling Point: 244.5±19.0 °C(Predicted)
• Appearance: /
• Density: 0.957±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.96±0.10(Predicted)
• CAS DataBase Reference: tert-butyl methyl(2-(methylamino)ethyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl methyl(2-(methylamino)ethyl)carbamate(112257-19-9)
• EPA Substance Registry System: tert-butyl methyl(2-(methylamino)ethyl)carbamate(112257-19-9)

Safety Data

• Hazardous Substances Data: 112257-19-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Bumetanide is utilized as a diuretic agent for the treatment of edema and fluid retention. It functions by increasing urine output, which aids in the removal of excess water and salt from the body, thus alleviating the symptoms of swelling and fluid buildup in patients suffering from heart failure, liver disease, and kidney disease.
Used in Cardiology:
In the field of cardiology, Bumetanide is employed as a therapeutic intervention for patients with heart failure. It helps manage the symptoms by reducing the volume of fluid that the body retains, thereby decreasing the workload on the heart and improving cardiac function.
Used in Nephrology:
Bumetanide is applied in nephrology to address conditions involving kidney disease where the kidneys are unable to efficiently remove excess fluid and salt from the body. Its diuretic properties assist in mitigating fluid retention and associated complications.
Used in Hepatology:
In hepatology, Bumetanide serves as a treatment for liver disease-induced fluid retention. It is particularly beneficial in cases where the liver's capacity to process and excrete fluids is compromised, helping to alleviate the associated discomfort and health risks.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 110-70-3 N,N`-dimethylethylenediamine 
• 34619-03-9 tert-butyldicarbonate 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 133171-78-5 N-(tert-butoxycarbonyl)-N-methyl-2-ethylamine 
• 122734-31-0 {2-[(4-Methoxy-phenoxycarbonyl)-methyl-amino]-ethyl}-methyl-carbamic acid tert-butyl ester 
• 135685-08-4 N-<2--N-methylamino>ethyl>-N-methyl-3-nitro-4-<(phthalimidooxy)methyl>benzenesulfonamide 
• 294173-05-0 Z-D-Val-Leu-Lys(Z)-N(Me)-(CH₂)2-N(Me)-Boc 
• 294173-06-1 Z-D-Ala-Phe-Lys(Z)-N(Me)-(CH₂)2-N(Me)-Boc 
• 637330-39-3 N,N'-dimethyl-N-benzyl-[4-(2,3,4-tri-O-tert-butyldimethylsilyl-β-D-glucopyranosyl)uronate-3-nitrobenzoyloxycarbonyl]-N'-(tert-butoxycarbonyl)ethylenediamine 
• 848826-52-8 methyl-(2-{methyl-[2,4,6-tris-(tert-butyl-dimethyl-silanyloxymethyl)-phenoxycarbonyl]-amino}-ethyl)-carbamic acid tert-butyl ester 
• 848826-75-5 {2-[(4-hydroxymethyl-phenoxycarbonyl)-methyl-amino]-ethyl}-methyl-carbamic acid tert-butyl ester 
• 870449-83-5 trans-3-(3,4,5-trimethoxyphenyl)acrylic acid 3-[[2-(tert-butoxycarbonylmethylamino)ethyl]methylamino]propyl ester 
• 916084-94-1 4-{[2-(tert-butoxycarbonyl-methyl-amino)-ethyl]-methyl-carbamoyloxy}-3,5-bis-(tert-butyl-dimethyl-silanyloxymethyl)-benzoic acid ethyl ester 
• 916084-87-2 (2-{[2,6-bis-(tert-butyl-dimethyl-silanyloxymethyl)-4-prop-2-ynylcarbamoyl-phenoxycarbonyl]-methyl-amino}-ethyl)-methyl-carbamic acid tert-butyl ester 
• 945410-19-5 C₁₉H₂₄N₂O₇ 
• 945410-21-9 C₂₈H₄₂N₂O₁₀ 
• 916084-95-2 4-{[2-(tert-butoxycarbonyl-methyl-amino)-ethyl]-methyl-carbamoyloxy}-3,5-bis-hydroxymethyl-benzoic acid ethyl ester 

Relevant articles and documents

Chemical Synthesis of Native S-Palmitoylated Membrane Proteins through Removable-Backbone-Modification-Assisted Ser/Thr Ligation

The preparation of native S-palmitoylated (S-palm) membrane proteins is one of the unsolved challenges in chemical protein synthesis. Herein, we report the first chemical synthesis of S-palm membrane proteins by removable-backbone-modification-assisted Ser/Thr ligation (RBMGABA-assisted STL). This method involves two critical steps: 1) synthesis of S-palm peptides by a new γ-aminobutyric acid based RBM (RBMGABA) strategy, and 2) ligation of the S-palm RBM-modified peptides to give the desired S-palm product by the STL method. The utility of the RBMGABA-assisted STL method was demonstrated by the synthesis of rabbit S-palm sarcolipin (SLN) and S-palm matrix-2 (M2) ion channel. The synthesis of S-palm membrane proteins highlights the importance of developing non-NCL methods for chemical protein synthesis.

Fast Cyclization of a Proline-Derived Self-Immolative Spacer Improves the Efficacy of Carbamate Prodrugs

Self-immolative (SI) spacers are sophisticated chemical constructs designed for molecular delivery or material degradation. We describe herein a (S)-2-(aminomethyl)pyrrolidine SI spacer that is able to release different types of anticancer drugs (possessing either a phenolic or secondary and tertiary hydroxyl groups) through a fast cyclization mechanism involving carbamate cleavage. The high efficiency of drug release obtained with this spacer was found to be beneficial for the in vitro cytotoxic activity of protease-sensitive prodrugs, compared with a commonly used spacer of the same class. These findings expand the repertoire of degradation machineries and are instrumental for the future development of highly efficient delivery platforms.

An efficient methodology to introduce o-(aminomethyl)phenyl-boronic acids into peptides: alkylation of secondary amines

Current approaches for incorporating boronic acids into peptides require one of the following: the synthesis of commercially unavailable pinacol-protected boronate ester amino acid building blocks, amidation of small-molecule amine-containing boronic acids, or reductive amination of amine residues with 2-formylphenyl boronic acid. These methods have drawbacks, such as the use of excess starting materials, the lack of reactive-site specificity, or the inability to add multiple boronic acids in solution. In addition, several of these approaches do not allow for incorporation of the critical o-aminomethyl functionality that allows for binding of saccharides under physiological conditions. In this work, we report three methods to functionalize synthetic peptides with boronic acids using solid-phase and solution-phase chemistries by alkylating a secondary amine with o-(bromomethyl)phenylboronic acid. Solution-phase chemistries afforded the highest yields, and were used to synthesize seven complex biotinylated multi-boronic acid peptides.

Photochemical cleavage reaction of 8-quinolinyl sulfonates that are halogenated and nitrated at the 7-position

Photochemical bond-cleavage reactions are potentially useful in chemistry, bioorganic chemistry and medicinal chemistry. We previously reported on a photochemical cleavage reaction of 8-quinolinyl sulfonate (8-QS) derivatives in aqueous solution at neutra

Amplified Self-Immolative Release of Small Molecules by Spatial Isolation of Reactive Groups on DNA-Minimal Architectures

Triggering the release of small molecules in response to unique biomarkers is important for applications in drug delivery and biodetection. Due to low quantities of biomarker, amplifying release is necessary to gain appreciable responses. Nucleic acids have been used for both their biomarker-recognition properties and as stimuli, notably in amplified small-molecule release by nucleic-acid-templated catalysis (NATC). The multiple components and reversibility of NATC, however, make it difficult to apply in vivo. Herein, we report the use of the hybridization chain reaction (HCR) for the amplified, conditional release of small molecules from standalone nanodevices. We couple HCR with a DNA-templated reaction resulting in the amplified, immolative release of small molecules. We integrate the HCR components into single nanodevices as DNA tracks and spherical nucleic acids, spatially isolating reactive groups until triggering. This could be applied to biosensing, imaging, and drug delivery.

A new fluorogenic probe for the selective detection of carbon monoxide in aqueous medium based on Pd(0) mediated reaction

A coumarin-based fluorogenic probe, PCO-1, senses carbon monoxide (CO) selectively in HEPES buffer at pH 8.0 through the intramolecular cyclization-elimination pathway based on Pd(0) mediated reaction. The probe exhibits a 'turn-on' response of CO over a variety of relevant reactive oxygen, nitrogen and sulfur species. This journal is

New contributions to the drug profile of TNFα inhibitor SPD304: Affinity, selectivity and ADMET considerations

Tumor necrosis factor alpha (TNFα) is a relevant clinical target for the treatment of chronic inflammatory diseases. Currently, only few small molecules are known as direct inhibitors of TNFα. To date, none of these molecules has shown both an efficient a

Antibiotic modified anticancer compounds for the treatment of non-genetic anti-cancer and anticancer pharmaceutical composition comprising the same

The present invention relates to an antibiotic modified anti-cancer compound for gene non-toxic anticancer therapy and an anticancer pharmaceutical composition comprising the same. A method for treating mitochondria target using a compound according to th

Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines

Covalent modification of disease-associated proteins with small molecules is a powerful approach for achieving an increased and sustained pharmacological effect. To reduce the potential risk of nonselective covalent modification, molecular design of covalent inhibitors is critically important. We report herein the development of a targeted covalent inhibitor for mutated epidermal growth factor receptor (EGFR) (L858R/T790M) using α-chlorofluoroacetamide (CFA) as the reactive group. The chemically tuned weak reactivity of CFA was suitable for the design of third-generation EGFR inhibitors that possess the pyrimidine scaffold. The structure-activity relationship study revealed that CFA inhibitor 18 (NSP-037) possessed higher inhibition selectivity to the mutated EGFR over wild-type EGFR when compared to clinically approved osimertinib. Mass-based chemical proteomics analyses further revealed that 18 displayed high covalent modification selectivity for the mutated EGFR in living cells. These findings highlight the utility of CFA as a warhead of targeted covalent inhibitors and the potential application of the CFA-pyrimidines for treatment of non-small-cell lung cancer.

7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER

The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.